The addition of deep hyperthermia to gemcitabine-based chemoradiation may achieve enhanced survival in unresectable locally advanced adenocarcinoma of the pancreas.
Clin Transl Radiat Oncol
; 27: 109-113, 2021 Mar.
Article
em En
| MEDLINE
| ID: mdl-33598571
ABSTRACT
INTRODUCTION:
Driven by the current unsatisfactory outcomes for patients with locally advanced pancreatic cancer (LAPC), a biologically intensified clinical protocol was developed to explore the feasibility and efficacy of FOLFORINOX chemotherapy followed by deep hyperthermia concomitant with chemoradiation and subsequent FOLFORINOX chemotherapy in patients with LAPC.METHODS:
Nine patients with LAPC were treated according to the HEATPAC Phase II trial protocol which consists of 4 cycles of FOLFORINOX chemotherapy followed by gemcitabine-based chemoradiation to 56 Gy combined with weekly deep hyperthermia and then a further 8 cycles of FOLFORINOX chemotherapy.RESULTS:
One grade three related toxicity was reported and two tumours became resectable. The median overall survival was 24 months and 1 year overall survival was 100%.CONCLUSIONS:
Intensification of chemoradiation with deep hyperthermia was feasible in nine consecutive patients with LAPC.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Guideline
Idioma:
En
Revista:
Clin Transl Radiat Oncol
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Suíça